Physician profile
Patrick A Litam
NPI 1942655105
$1,423.62
in general payments reported to CMS, 2019-2025
11 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.66 · 2022: $994 · 2023: $92.73 · 2024: $112 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veracyte, INC. | $993.96 | 2022 | |
| Eisai INC. | $162.73 | 2019-2025 | |
| Daiichi Sankyo INC. | $69.65 | 2025 | Enhertu, Datroway |
| Pfizer INC. | $55.69 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.51 | 2019-2023 | |
| Pharming Healthcare, INC. | $22.75 | 2024 | Ruconest |
| Aveo Pharmaceuticals, INC. | $21.71 | 2023 | Fotivda |
| Emd Serono, INC. | $18.24 | 2025 | |
| Abbvie INC. | $17.35 | 2024 | |
| Morphosys, US INC. | $16.94 | 2023 | Monjuvi |
| Boston Scientific Corporation | $15.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Litam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.